Current scenario on pending abbreviated new drug application’s suitability petition

Vinitha, Goli and Muddukrishna, BS (2019) Current scenario on pending abbreviated new drug application’s suitability petition. Research Journal of Pharmacy and Technology, 12 (12). pp. 5985-5990. ISSN 0974-3618

[img] PDF
RMS - 00008016.pdf - Published Version
Restricted to Registered users only

Download (201kB) | Request a copy

Abstract

Suitability Petition (SP) is a petition (request) to Food and Drug Administration to permit the filing of an Abbreviated New Drug Application for a drug that differs from the Reference Listed Drug. According to FDA, response timeline is 90 days. While submitting the Suitability petition to the FDA the applicant should submit in the following format: a) Action Requested, b) Statement of Grounds, c) Environmental Assessment d) Economic Impact e) Certification by applicant. A type of citizen petition submitted in compliance with 21 CFR 10.30 requesting FDA to approve or disapprove a specific change. If FDA approves a SP, the generic manufacturer can file for approval of ANDA or 505(b) 2 or 351k application for the requested change. Suitability Petition contains information of the RLD and Proposed change (Comparisons) by Generics.

Item Type: Article
Uncontrolled Keywords: ANDA; FDA; suitability petition.
Subjects: Pharmacy > MCOPS Manipal > Pharmaceutical Quality Assurance
Depositing User: KMC Library
Date Deposited: 01 Jul 2020 06:47
Last Modified: 01 Jul 2020 06:47
URI: http://eprints.manipal.edu/id/eprint/155030

Actions (login required)

View Item View Item